HOME >> BIOLOGY >> NEWS
A new target for the treatment of breast cancer

The active ingredient in a drug currently being tested to treat rheumatoid arthritis might also one day serve as an effective means of treating one of the deadliest forms of breast cancer. Researchers with the U.S. Department of Energy's Lawrence Berkeley National Laboratory (Berkeley Lab) have demonstrated that inhibiting the activity of the protease enzyme known as TACE can deprive tumor cells of a key factor needed for their proliferation. TACE is strongly present in a form of breast cancer which responds poorly to current therapies.

"We have shown that inhibition of the TACE protease in breast cancer cells blocks the shedding of two critical growth factor proteins and results in an inhibition of a key signaling pathway that controls cell division," said Paraic Kenny, a post-doctoral cell biologist with the research group of Mina Bissell in Berkeley Lab's Life Sciences Division. "Based on analysis of cells grown in three-dimensional cultures, the inhibition of this protease results in the reversion of the malignant phenotype of these breast cancer cells and switches their behavior back to a phenotype very reminiscent of non-malignant breast epithelial cells."

Kenny is the co-author along with Bissell of a paper published in the Journal of Clinical Investigation entitled: Targeting TACE-Dependent EGFR-ligand Shedding in Breast Cancer. This paper presents the latest experimental results from an on-going investigation led by Bissell into the ecology of tumors.

It has long been Bissell's contention that "no tumor is an island." Tumor cells, she maintains, exist in the same microenvironment as healthy cells and must therefore appropriate normal physiological processes to facilitate their growth and spread. As she and her colleagues have repeatedly demonstrated, this idea can open up potential new avenues and targets for diagnostic and therapeutic applications.

For this latest paper, Kenny and Bissell looked into the pathwa
'"/>

Contact: Lynn Yarris
lcyarris@lbl.gov
510-486-5375
DOE/Lawrence Berkeley National Laboratory
11-Jan-2007


Page: 1 2 3

Related biology news :

1. Huntingtons disease study shows animal models on target
2. New target for HIV/AIDS drugs and vaccine discovered
3. When off-target is right on
4. Genomic analysis uncovers new targets for HIV vaccine
5. Bulls-eye -- Programs targeting math, science teacher shortage may get boost
6. Scientists take next step in understanding potential target for ovarian cancer treatment
7. On target
8. New way to target and kill antibiotic-resistant bacteria found
9. Weill Cornell team identifies potential new cancer drug target
10. CSHL scientists successfully target tumor microenvironment to stop cancer growth
11. Sleep deprivation affects airport baggage screeners ability to detect rare targets

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/20/2020)... ... March 20, 2020 , ... ImStem Biotechnology, ... cell (ESC) derived mesenchymal stem cells (hES-MSC), through a proprietary method using a ... autoimmune, and rare orphan diseases, today announced that the U.S. Food and Drug ...
(Date:3/13/2020)... ... 13, 2020 , ... Cryo-Cell International’s announcement is concurrent with ... Dr. Hal Boxmeyer and colleagues, which determined sample viability of 23.5 years and ... conditions. Cryo-Cell International marks the first family cord blood bank to release results ...
(Date:3/11/2020)... ... 11, 2020 , ... USARAD Holdings Inc., the leading US ... healthcare VC firms introduces a first of its kind COVID-19 screening program. The ... caused over 4,000 fatalities to date. Over the years, USARAD through its SecondOpinions.com ...
Breaking Biology News(10 mins):
(Date:2/10/2020)... , ... February 10, 2020 , ... R3 Medical Training ... March 13-14th, 2020 in Las Vegas. The course is hands on involving real ... For the past few years, the Comprehensive Stem Cell Training Course has received rave ...
(Date:2/5/2020)... ... February 05, 2020 , ... Rare Disease Day® ... by The National Organization for Rare Disorders (NORD), to raise awareness amongst the general ... ). The Balancing Act’s “Behind The Mystery” rare disease series will be ...
(Date:2/3/2020)... and CAMBRIDGE, Mass. (PRWEB) , ... February 03, ... ... Budapest with US offices in Cambridge, MA, announce that OmniType, the 11-locus, single ... (EAP) from today. OmniType is a best-in-class product featuring locus-multiplexing and short library ...
(Date:1/28/2020)... ... January 28, 2020 , ... ... biopharmaceutical R&D, today announced the release of Genedata Expressionist ® 13.5 ... the implementation of Multi-Attribute Methods (MAM) for characterizing and monitoring the quality ...
Breaking Biology Technology:
Cached News: